Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

Exclusion Criteria

• •1. Uncontrolled infection, temperature≥38℃
• •2. patients with bone marrow dysplasia and other hematopoietic dysfunction , or accepted stem cell or bone marrow transplant in 3 months before recruitment
• •3. undergoing any other clinical trial in 4 weeks before recruitment
• •4. undergoing radiotherapy in 4 weeks before recruitment
• •5. Patients with other malignant tumors who have not been cured or have brain metastasis
• •6. Liver function: ALT, TBIL, AST \> 2.5 ULN; If due to liver metastasis, ALT, TBIL, AST \> 5 ULN; Renal function: Cr\>1.5; Obvious abnormalities in electrocardiogram
• •7. Severe heart, kidney, liver and other important organs chronic diseases
• •8. severe and uncontrolled diabetes
• •9. Pregnancy or lactation in women or women of childbearing age refused to accept contraception
• •10. People with allergic diseases or allergies, or who are allergic to this or other genetically engineered Escherichia coli-derived biological products
• •11. Suspected or confirmed drug use, drug abuse, alcoholics
• •12. Severe mental or neurological disorders affecting informed consent and/or adverse effect presentation or observation
• •13. HIV positive
• •14. Syphilis infection
• •15. The investigator believes that the patient's condition is not suitable for this clinical study.